方法：计算机检索Cochrane Library、Pubmed、Medline、中国数字医院图书馆(www.chkd.cnki.net)全文数据库、万方数据库、中文科技期刊全文数据库(VIP)，检索时间为建库至2014-01，并辅以手工检索，全面收集有关鼠神经生长因子治疗外伤性视神经病变的对照研究，评价纳入研究质量，提取有效数据，并进行Meta分析。

结果：符合纳入标准的对照试验文献7篇，合计399眼，鼠神经生长因子参与治疗后，优势比OR=3.78，95%CI为\〖2.35，6.06\〗，P<0.01，差异具有统计学意义。

结论：从现有的临床证据来看，鼠神经生长因子参与治疗能提高外伤性视神经病变的治疗有效率。但还需要更多高质量的多中心、随机、双盲临床试验来进一步验证和支持。

METHODS: We searched the Cochrane Library, Pubmed, Medline,CNKI, Wanfang database and VIP to collect randomized controlled trials(RCTs)of using mouse nerve growth factor for TON. The quality of the included trials was assessed and poor-qualified trials were eliminated before the meta-analysis was conducted.

RESULTS: Seven RCTs with a total of 399 eyes included were retrieved, and OR=3.78 with a 95%CI of \〖2.35, 6.06\〗, the difference was significant(P<0.01).

CONCLUSION: The existing evidence supports that the prognosis of TON is better when mouse nerve growth factor are adopted in treatment, but there is still a need for well-planned, large-scale and multicenter RCTs to verify it.